Xenon Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Xenon Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Xenon Pharmaceuticals Inc recorded a cumulative net loss of $-409 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -41.7%.

However, within the Healthcare sector 501 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3885, from total ROA ranking in the first quarter of 2026 at 4606.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	91.98 %	86.2 %	-21.96 %	-27.19 %	-23.71 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-409	-383	-346	-306	-278
Return On Assets (TTM)	-41.7 %	-46.39 %	-51.98 %	-43.14 %	-36.28 %
XENE's Total Ranking	# 3885	# 4606	# 3949	# 3895	# 3864
Total Assets (TTM) in million	1,296	1,387	633	609	675
Seq. Total Assets Change	-6.56 %	119.03 %	3.95 %	-9.75 %	-9.38 %
Seq. Net Income Change	-	-	-	-	-

XENE's 5 Years Annual ROA >> Back to XENE Management Effectiveness >> Compare XENE ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 201
Sector	# 502
Overall	# 3776

Return On Assets Statistics
High	Average	Low
-4.26 %	-29.81 %	-59.19 %
(Jun 30 2015)		(Dec 31 2017)

Financial Statements
Xenon Pharmaceuticals Inc 's Assets	$ 1,296 million	XENE's Balance sheet
Xenon Pharmaceuticals Inc 's Income	$ -111 million	Quarterly XENE's Income Statement
XENE's Income by Division		See XENE's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-16.16 %	-17.3 %	27.84 %	32.21 %	207.76 %
Total Assets in million	670	800	967	756	572
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-346	-234	-182	-125	-77
Annual Return On Assets	-51.6 %	-29.31 %	-18.87 %	-16.52 %	-13.48 %

XENE's 5 Years Annual ROA >> Back to XENE Management Effectiveness >> Compare XENE ROA to its Competitors

More Return On Assets Ratios
XENE's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
XENE's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for XENE's Competitors
Subscribers only: Roa for Xenon Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for XENE's Customers

You may also want to know
XENE's Roi	XENE's Inventory Turnover Ratio	XENE's Growth Rates	XENE's Dividend Comparisons
	XENE's Profitability Ratios	XENE's Asset Turnover Ratio	XENE's Dividend Growth
XENE's Roe	XENE's Valuation Ratios	XENE's Financial Strength Ratios	XENE's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:24:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.